Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide with PET Regimen for Angioimmunoblastic T-cell Lymphoma
NCT03273452Phase 2Unknown
- Sponsor
- Qingdao University
- Start
- Mar 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in angioimmunoblastic T-cell lymphoma (AITL), sponsored by Qingdao University. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on NCT03273452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03273452.